A 31-year-old woman with uncontrolled Graves' disease presented with general fatigue and headache. Laboratory testing showed an exacerbation of hyperthyroidism [free triiodothyronine, 14.16 pg/mL; free thyroxine, 3.14 ng/dL; thyroid stimulating hormone (TSH), <0.01 μIU/mL] and increases in the serum anti-TSH receptor antibody [TSH receptor antibody, 35.86 IU/mL (normal <2.0 IU/mL) and thyroid stimulating antibody, 2,065% (normal <120%)] and soluble interleukin-2 receptor (sIL-2R, 1,362 U/mL, normal 122-496 U/mL) levels. Computed tomography revealed thymic enlargement, cervical and axillary lymphadenopathy, and hepatosplenomegaly along with diffuse thyroidal en-
largement. After administering methimazole and propranolol for a few days, an improvement in the hyperthyroidismrelated symptoms was thus achieved. Three months later, the organomegaly resolved (Picture) and the serum sIL-2R levels normalized.
In patients with Graves' hyperthyroidism, such symptoms as thymic hyperplasia, splenomegaly and lymphadenopathy may sometimes occur, and such complications may be due to TSH receptor antibody stimulation and excessive thyroid hormone levels (1). Elevated serum sIL-2R levels may occur in parallel with an exacerbation of thyrotoxicosis (2) . Therefore, not only lymphoproliferative disorders, but also thyrotoxicosis should be considered when making a differential diagnosis of lymphadenopathy and/or hepatosplenomegaly.
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